Neuphoria Therapeutics
NEUP
4 hedge funds and large institutions have $3.4M invested in Neuphoria Therapeutics in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 3 reducing their positions, and 1 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
20% less funds holding
Funds holding: 5 → 4 (-1)
38% less capital invested
Capital invested by funds: $5.51M → $3.4M (-$2.11M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSM
Light Sky Macro
New York
|
-$416K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$10.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$10.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WP
1
Woodline Partners
San Francisco,
California
| $1.37M | -$10.9K | -83 | -0.6% |
|
|
LSM
2
Light Sky Macro
New York
| $1.34M | -$416K | -3,159 | -19% |
|
|
BI
3
BVF Inc
San Francisco,
California
| $692K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$10.7K | -81 | -94% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| – | -$1K | -8 | Closed |
|
NEUP Hedge Fund Activity: Q1 2022 in Review
4 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q1 2022, worth a combined $3.4M — down 38% from $5.51M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NEUP and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 0 added.
The largest seller was Light Sky Macro, cutting an estimated $416K.
- 4 institutional investors held Neuphoria Therapeutics (NEUP) as of Q1 2022, down from 5 in Q4 2021.
- Funds reported $3.4M of Neuphoria Therapeutics stock for Q1 2022, down 38% quarter-over-quarter.
- 0 funds opened new Neuphoria Therapeutics positions in Q1 2022 and 1 closed out, a net change of -1 holder.
- The largest Neuphoria Therapeutics seller in Q1 2022 was Light Sky Macro, an estimated $416K sold.
Based on aggregated 13F filings for Q1 2022.